Table 7.
Comp. | MIC [μM] | |||
---|---|---|---|---|
MA 330/80 | MS | MM | ||
1 14-d | 2 21-d | 3 3-d | 21-d | |
1a | 125 | 125 | 213 | 106 |
1b | 62.5 | 125 | 104 | 52 |
1c | 32 | 62.5 | 51 | 25.5 |
1d | 32 | 32 | 24.9 | 12.5 |
1e | 62.5 | 62.5 | 16.2 | 32.5 |
1f | 32 | 32 | 15.8 | <3.9 |
1g | 16 | 16 | 15.4 | <3.8 |
1h | 8 | 16 | 15.0 | <3.7 |
1i | 62.5 | 125 | 203 | 51 |
1j | 62.5 | 125 | 6.2 | 50 |
1k | 32 | 62.5 | 390 | 98 |
1l | 32 | 62.5 | 382 | 191 |
1m | 16 | 32 | 30.7 | 15.4 |
1n | 16 | 16 | 15.0 | 15.0 |
1o | 16 | 16 | 7.3 | 7.3 |
1p | 16 | 16 | 7.1 | 7.1 |
INH | > 250 | > 250 | 117 | 467 |
EMB | 16 | 16 | – | – |
OFLX | 32 | 62.5 | – | – |
CPX | – | – | 0.4 | 0.8 |
1 14-d, 14-Day cultivation; 2 21-d, 21-day cultivation; 3 3-d, 3-day cultivation. The most promising values of compounds´ in vitro antimycobacterial activity (MIC ≤ 8 μM) were indicated in gray cells of Table 7.